West Pharmaceutical Services, Inc. (WST) financial statements and ratios from SEC XBRL: revenue $3.07B (TTM), net margin 16.1%, revenue growth 6.3% YoY, P/E 43.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $3.07B |
| Net Margin | 16.1% |
| Revenue Growth (YoY) | 6.3% |
| EPS Growth (YoY) | 1.2% |
| FCF Growth (YoY) | 69.6% |
| P/E Ratio | 43.7 |
| EV / EBITDA | 28.1 |
| Price / Book | 8.36 |
| Price / Sales | 7.43 |
| FCF Yield | 2.1% |
| DCF Value (model) | $134.09 |
| DCF Upside vs Price | -62.1% |
| Altman Z-Score | 16.96 (safe) |
| Piotroski F-Score | 7/9 |
| Sector P/E (Healthcare) | 21.6 |
WST overview · WST earnings · WST KPIs · WST investor relations · WST ownership · WST peers · WST filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.